Clinical trials: Poverty
Type 2 Diabetes Mellitus
Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
The primary purpose of this study is to evaluate the efficacy of voglibose versus acarbose combined with metformin in participants with type 2 diabetes mellitus (T2DM) by evaluating levels of glycosylated hemoglobin.
- Trial name
- NCT02049814
- Testing
- Metformin, Voglibose, Acarbose
- Where
- 18 sites in China
- Volunteers
- 494 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin
This study will evaluate the effects of treatment with vildagliptin and metformin as initial combination in newly diagnosed patients with type 2 diabetes who have very high levels of HbA1c and/or fasting plasma glucose.
- Trial name
- NCT00468039
- Testing
- vildagliptin + metformin
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Novartis
Tobacco Use Disorder, Substance Use Disorders
A Digital Smoking Cessation Intervention for Adults With Substance Use Disorder
Adults with substance use disorder (SUD) tend to have started smoking at a younger age and are more likely to be heavy smokers. Due to the many conflicting priorities in this population, smoking cessation is often relegated and…
- Trial name
- NCT04419922
- Testing
- Smartphone Contingency Management Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- BrightView LLC
Gaucher's Disease
A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers
The primary objective of the study is to evaluate dose proportionality and pharmacokinetics for three different dose levels of eliglustat after single and repeated administration.
- Trial name
- NCT06188325
- Testing
- Eliglustat
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Sanofi
Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
The purpose of this study is to to evaluate the effect of ASP0367 on improvement of aerobic capacity relative to placebo, as well as evaluate the safety and tolerability of ASP0367 relative to placebo.
- Trial name
- NCT04855201
- Testing
- Bocidelpar
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy
Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects
The purpose of this study is to determine if the relative difference in Pharmacokinetics (PK) between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single…
- Trial name
- NCT00727064
- Testing
- Desvenlafaxine Succinate Sustained-Release (DVS SR), Venlafaxine Extended Release (VEN ER)
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Knee Osteoarthritis
Catabolic Marker Levels After Platelet Poor Plasma (PPP) Lavage
The purpose of this study is to understand how the components of osteoarthritic knee joint fluid (synovial fluid) change after lavage treatment with platelet poor plasma.
- Trial name
- PPP (NCT03120988)
- Testing
- Lavage with Platelet Poor Plasma (PPP)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Regenexx, LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
The goal of this clinical trial is to evaluate the similarities in efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes who have poor glycemic control after metformin treatment.
- Trial name
- NCT06339086
- Testing
- Semaglutide Injection, Semaglutide Injection(Ozempic®), Metformin
- Volunteers
- 478 people
- Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd.